Drug intelligence / Profile preview

LY-2623091

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY‑2623091 is a selective, orally active, nonsteroidal, competitive mineralocorticoid receptor antagonist developed by Eli Lilly for the treatment of essential hypertension and renal failure. It blocks the actions of aldosterone and other mineralocorticoid receptor ligands at the receptor level. The drug reached phase II clinical trials for essential hypertension but development was discontinued. Its mechanism involves antagonism of the mineralocorticoid receptor (NR3C2), which regulates genes involved in ion and water transport, thereby affecting blood pressure regulation[2][6][3].

Other names: (E)-1-(5-((E)-(3-Fluorodibenzo(b,E)oxepin-11(6H)-ylidene)methyl)-1-((R)-1-morpholinopropan-2-yl)-1H-benzo(d)imidazol-2(3H)-ylidene)urea

Targets

MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on LY-2623091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY-2623091.

Explore the full profile